Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 21;16(5):101260.
doi: 10.1016/j.cels.2025.101260. Epub 2025 Apr 10.

Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence

Affiliations

Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence

Caleb R Perez et al. Cell Syst. .

Abstract

The anti-tumor function of engineered T cells expressing chimeric antigen receptors (CARs) is dependent on signals transduced through intracellular signaling domains (ICDs). Different ICDs are known to drive distinct phenotypes, but systematic investigations into how ICD architectures direct T cell function-particularly at the molecular level-are lacking. Here, we use single-cell sequencing to map diverse signaling inputs to transcriptional outputs, focusing on a defined library of clinically relevant ICD architectures. Informed by these observations, we functionally characterize transcriptionally distinct ICD variants across various contexts to build comprehensive maps from ICD composition to phenotypic output. We identify a unique tonic signaling signature associated with a subset of ICD architectures that drives durable in vivo persistence and efficacy in liquid, but not solid, tumors. Our findings work toward decoding CAR signaling design principles, with implications for the rational design of next-generation ICD architectures optimized for in vivo function.

Keywords: CAR T cells; T cell signaling; T cells; chimeric antigen receptors; immunotherapy; intracellular signaling domains; persistence; pooled screens; single-cell RNA sequencing; tonic signaling.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.E.B. is a founder, consultant, and equity holder of Kelonia Therapeutics and Abata Therapeutics. M.V.M. is an inventor on patents related to adoptive cell therapies, held by the Massachusetts General Hospital (some licensed to Promab and Luminary) and the University of Pennsylvania (some licensed to Novartis). M.V.M. receives grant/research support from Kite Pharma and Moderna; serves as a consultant for multiple companies involved in cell therapies; holds equity in 2SeventyBio, A2Bio, Affyimmune, BendBio, Cargo, Century Therapeutics, Neximmune, Oncternal, and TCR2; and serves on the Board of Directors of 2Seventy Bio. C.R.P. is currently employed at TwoStep Therapeutics. K.S.G. is currently employed at Ginkgo Bioworks, Inc.

Update of

References

    1. June CH, and Sadelain M (2018). Chimeric Antigen Receptor Therapy. N. Engl. J. Med 379, 64–73. - PMC - PubMed
    1. Majzner RG, and Mackall CL (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med 25, 1341–1355. - PubMed
    1. Cappell KM, and Kochenderfer JN (2023). Long-term outcomes following CAR T cell therapy: what we know so far. Nature Reviews Clinical Oncology 2023 20:June 20, 359–371. - PMC - PubMed
    1. Shah NN, and Fry TJ (2019). Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol 16, 372–385. - PMC - PubMed
    1. Morris EC, Neelapu SS, Giavridis T, and Sadelain M (2021). Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol, 1–12. - PMC - PubMed

MeSH terms

Substances